| Name | 4basebio |
|---|---|
| Epic | 4BB |
| Isin | GB00BMCLYF79 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1,275.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £163.34 | Debt ratio | n/a |
| Shares in issue | 12.81 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -69.97 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -42 | 52-week high / low | 500.00p / 1,820.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | 4basebio |
|---|---|
| Address | 25 Norman Way, Over, Cambridge, United Kingdom, CB24 5QE |
| Telephone | +44 (0)1223 967943 |
| Website | http://www.4basebio.com/ |
| Director | Position |
|---|---|
| Dr Heikki Lanckriet | CEO |
| Mr David John Roth | CFO |
| Mr Hansjörg Plaggemars | Non-Executive Director |
| Mr Joseph Manuel Fernández | Non-Executive Director |
| Mr Timothy Paul McCarthy | Non-Executive Chairman |
| Mr Maria Del Pilar de la Huerta | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 2.12 | 1.27 | 0.79 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 5.79 | 4.06 | 2.3 |
| Inventory / work in progress | 0.13 | 0.16 | 0.13 |
| Trade and other receivables | 0.05 | 0.05 | 0.04 |
| Cash and equivalents | 4.35 | 9.59 | 15 |
| Other current assets and asset held for resale | 1.36 | 0.85 | 0.34 |
| Total of all assets | 11.69 | 14.7 | 17.81 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 1.52 | 1.52 | 0.81 |
| Long term liabilities | 3.05 | 1.48 | 1.54 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 4.57 | 3.01 | 2.35 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 7.12 | 11.7 | 15.46 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 11.13 | 11.13 | 11.13 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -18.73 | -13.57 | -10.34 |
| Share premium account | 0.71 | 0.71 | 0.71 |
| Total equity | 7.12 | 11.7 | 15.46 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -5.84 | -3.53 | -0.62 |
| Pre-tax profit | -5.93 | -3.64 | -0.72 |